Thérèse Bocklage

Dr. Thérèse Bocklage

Department of Pathology, University of Kentucky College of Medicine and Markey Cancer Center, Lexington, KY 40536, USA
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2022 in Endocrine Pathology
Verified
Journal Article
Open access
PDF file
DADerek B. Allison
Derek B. Allison
JRJustin Rueckert
Justin Rueckert
VCVirgilius Cornea
Virgilius Cornea
CLCortney Y. Lee
Cortney Y. Lee
JDJulie Dueber
Julie Dueber
TBThérèse Bocklage
Thérèse Bocklage
In this report, we present a high-grade thyroid carcinoma with an NSD3::NUTM1 fusion detected on expanded next-generation sequencing testing. Nuclear protein of the testis (NUT) carcinomas comprise high-grade, aggressive tumors characterized by rearrangements of the NUTM1 gene with various partner genes, most commonly the bromodomain protein genes BRD4 and BRD3. Approximately 10% of NUT carcinomas contain an NSD3::NUTM1 fusion. NUT carcinomas manifest as poorly differentiated or undifferentiated squamous carcinomas, and 33% show areas of mature squamous differentiation. Only exceptionally have NUT carcinomas shown histology discordant from poorly differentiated/undifferentiated squamous carcinoma, and a thyroid NUT carcinoma with histologic thyrocyte differentiation has not been described to date. Our patient’s tumor exhibited mixed cytologic features suggestive of squamoid cells or papillary thyroid carcinoma cells. Overt squamous differentiation was absent, and the tumor produced colloid in poorly formed follicles. Immunophenotypically, the carcinoma was consistent with thyrocyte differentiation with expression of monoclonal PAX8, TTF1, and thyroglobulin (the last predominantly in extracellular colloid). There was zero to < 2% reactivity for proteins typically diffusely expressed in NUT carcinoma: p40, p63, and cytokeratins 5/6. NUT protein expression was equivocal, but fluorescence in situ hybridization confirmed a NUTM1 rearrangement. This exceptional case suggests that NUTM1 fusions may occur in an unknown number of aggressive thyroid carcinomas, possibly with distinctive histologic features but with thyrocyte differentiation. Recognition of this entity potentially has significant prognostic implications. Moreover, thyroid carcinomas with NUTM1 fusions may be amenable to treatment with NUT carcinoma-targeted therapy such as a bromodomain and extraterminal domain protein small molecular inhibitor (BETi).

1 April 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
TGTong Gan
Tong Gan
KSKurt B. Schaberg
Kurt B. Schaberg
DHDaheng He
Daheng He
AMAkila Mansour
Akila Mansour
HKHarit Kapoor
Harit Kapoor
TBThérèse Bocklage
Thérèse Bocklage
Colorectal cancer (CRC) remains the second most common cause of cancer deaths in the United States. Approximately 52 980 people in the United States will die from CRC in 2021. The incidence among those older than 65 years has been steadily declining.1 However, the incidence in those aged between 50 to 64 years has been increasing by 1% annually, and that among patients younger than 50 years has been increasing by 2% annually. Similarly, mortality rates have increased by 1.3% annually in those younger than 50 years.1-3 Modifiable factors for CRC include tobacco exposure, alcohol consumption, poor diet, and obesity; these are major contributors to the increased incidence and mortality.4

1 March 2019 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
ASAdriana Sanchez
Adriana Sanchez
TBThérèse Bocklage
Thérèse Bocklage

24 November 2020 in Immunobiology
Verified
Journal Article
Closed access
DHDalia Haydar
Dalia Haydar
RGRene Gonzalez
Rene Gonzalez
BGBeth A. Garvy
Beth A. Garvy
SGSylvie Garneau-Tsodikova
Sylvie Garneau-Tsodikova
NCNishad Thamban Chandrika
Nishad Thamban Chandrika
DFDavid J. Feola
David J. Feola

11 April 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
FHFaisal A. Hassan
Faisal A. Hassan
CSCamryn Slone
Camryn Slone
RMRobert J. McDonald
Robert J. McDonald
JDJulie C. Dueber
Julie C. Dueber
AAAdeel M. Ashraf
Adeel M. Ashraf
DADerek B Allison
Derek B Allison
Thyroid carcinomas are driven by diverse molecular alterations, but the tumor suppressor gene folliculin (FLCN), best known for its role in Birt–Hogg–Dubé (BHD) syndrome, has received limited attention in thyroid tumors. Here, we describe two thyroid tumors with pathogenic FLCN alterations—one germline and one somatic—and analyze the broader prevalence and significance of FLCN in thyroid carcinomas using multiple large sequencing datasets, including ORIEN-AVATAR. Patient 1, with a germline FLCN mutation and a history of BHD syndrome, presented with a well-circumscribed oncocytic adenoma. Molecular testing confirmed biallelic FLCN inactivation, but no additional mutations or aggressive features were observed, and the patient remained disease-free post-thyroidectomy. Patient 2 harbored a somatic FLCN mutation in an oncocytic poorly differentiated thyroid carcinoma, which exhibited extensive angioinvasion, high proliferative activity, and concurrent TP53 and RB1 mutations. The tumor progressed with metastatic disease despite multimodal treatment. Thyroid carcinomas revealed FLCN alterations in 1.1% of cases. Pathogenic mutations were rare but associated with oncocytic morphology, while homozygous deletions occurred more frequently in genomically unstable tumors, including anaplastic thyroid carcinoma. These findings suggest FLCN mutations may act as early oncogenic drivers in oncocytic thyroid neoplasms, while deletions represent secondary events in aggressive tumor evolution. The lack of FLCN coverage in standard thyroid molecular panels likely underestimates its clinical relevance. Including FLCN in genetic testing could improve tumor detection and characterization, particularly in BHD patients who may benefit from routine thyroid screening. Further studies are needed to clarify FLCN’s role in thyroid cancer pathogenesis.

1 August 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
JING DIJING DI
JING DI
AAAli Alhaidary
Ali Alhaidary
CWChi Wang
Chi Wang
JLJinge Liu
Jinge Liu
Sainan WeiSainan Wei
Sainan Wei
TBThérèse Bocklage
Thérèse Bocklage
Nuclear Protein in Testis (NUT)-rearranged tumors comprise predominantly NUT carcinoma but also include certain lymphomas, leukemias, skin appendage tumors, and sarcomas. Although histologically diverse, all are genetically identified by oncogenic rearrangement in the NUTM1 gene. Many fusion partners occur, and NSD3 is NUT carcinoma’s third most common partner. Herein, we present a case of a 26-year-old man with an NSD3::NUTM1 fusion sarcoma. The patient presented at the age of 13 months with a scalp nodule. Over the next 24 years, he experienced five local recurrences and ultimately expired of a rapidly progressive recurrence. His treatment included surgical resections, radiation, and various chemotherapies. Deceptively, the clinical presentation and histopathology aligned with a malignant peripheral nerve sheath tumor, a diagnosis rendered at initial resection with concurrence by a national soft tissue tumor expert. The patient’s exceptionally long survival could be due to NSD3 as the fusion partner, aided by the initial small tumor size and young patient age. Thus, this case expands NUT fusion sarcomas’ histologic and immunohistochemical profile to include mimicking a malignant peripheral nerve sheath tumor (MPNST). Additionally, it indicates that the NSD3::NUTM1 fusion can drive sarcoma genesis.